Skip Navigation

Lee M. Nadler, MD


Medical Oncology

Make an Appointment

Physician

  • Senior Vice President, Experimental Medicine
  • Physician
  • PMC Chair
  • Virginia and D.K. Ludwig Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bone marrow transplant
  • Immunotherapy
  • Lymphoma

Diseases Treated

  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin

Contact Information

  • Office Phone Number617-632-3331
  • Fax617-632-3541

Bio

Dr. Nadler received his MD from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center and training at the National Cancer Institute in tumor immunology, he completed a medical oncology fellowship at DFCI, where he joined the staff in 1980. During his tenure at DFCI, he has served as chief and chair of several departments.

Board Certification:

  • Internal Medicine, 1976

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology
  • National Cancer Institute, Immunology

Residency:

  • Columbia-Presbyterian Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • Richard and Hinda Rosenthal Foundation Award, AACR 1998
  • Association of American Physicians 2000
  • American Society for Clinical Investigation 1989
  • Joseph H. Burchenal Clinical Research Award, AACR 2002
  • Virginia and D.K. Ludwig Professor 2002

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 540
Boston MA, 02215
Get Directions

Research

Induction of Alloantigen-Specific Anergy for Allogeneic HSCT and Antitumor Immunity

Our laboratory focuses on translational bench-to-bedside and bedside-to-bench research. First, we are investigating the mechanisms of tolerance induction to improve the outcome of allogeneic stem cell transplantation. Second, we are attempting to induce antigen-specific tumor immunity.

Our studies of anergy and tolerance are direct extensions of our discovery and characterization of the B7 family of costimulatory molecules. Blockade of the B7 family is both necessary and sufficient to induce alloantigen-specific anergy. We have shown that anergy is an active signaling process. Following extensive preclinical studies, we embarked on a clinical trial. The objective of this study was to induce tolerance of donor T cell antigens specific to host antigen anergy ex vivo through blockade of B7 costimulation. Induction of antigen-specific tolerance would eliminate or sharply curtail the need for nonspecific prophylactic immunosuppression and for the subsequent toxic and often inefficacious treatment of severe acute or chronic graft-versus-host disease (GVHD). Similarly, retention of a mature T cell component in the graft with its residual repertoire intact could facilitate engraftment and eliminate the risks of lymphoproliferative disease and increased relapse after transplant that currently attend global T cell depletion strategies.

We have completed two phase I studies using anti-B7 blockade to induce alloantigen-specific anergy in patients undergoing haploidentical human stem cell transplantation. We have demonstrated feasibility, less than expected incidence of GVHD, and fewer than expected infections. Going forward, we are focusing on the retention of pathogen and tumor-specific immunity.

Our studies in antigen-specific antitumor immunity have focused on the identification and clinical translational of universal tumor antigens. We have shown that hTERT and CYP1B1 are expressed in most human tumors with limited expression in normal tissues. Human T cells directed against these antigens exist in the T cell repertoire of normal individuals and patients with cancer. T cells directed against these antigens can be generated ex vivo, and these T cells can kill human tumor cells in an HLA-restricted, antigen-restricted fashion. Each of these universal tumor antigens has been taken to the clinic to treat patients with advanced-stage multiply relapsed cancer. A phase I trial of hTERT peptide-pulsed dendritic cells demonstrated feasibility, safety, and the generation of peptide-specific T cells. We are now extending this trial. We have also conducted a DNA vaccine trial of CYP1B1. Again, no significant toxicities were observed and patients generated anti-CYP1B1 specific T cells.

Barbon CM, Davies JK, Voskertchian A, Kelner RH, Brennan LL, Nadler LM, Guinan EC. Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells. Am J Transplant. 2014 Feb; 14(2):305-18.
View in: PubMed

Davies JK, Barbon CM, Voskertchian A, Nadler LM, Guinan EC. Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant. 2012; 21(9):2047-61.
View in: PubMed

Shamoon H, Center D, Davis P, Tuchman M, Ginsberg H, Califf R, Stephens D, Mellman T, Verbalis J, Nadler L, Shekhar A, Ford D, Rizza R, Shaker R, Brady K, Murphy B, Cronstein B, Hochman J, Greenland P, Orwoll E, Sinoway L, Greenberg H, Jackson R, Coller B, Topol E, Guay-Woodford L, Runge M, Clark R, McClain D, Selker H, Lowery C, Dubinett S, Berglund L, Cooper D, Firestein G, Johnston SC, Solway J, Heubi J, Sokol R, Nelson D, Tobacman L, Rosenthal G, Aaronson L, Barohn R, Kern P, Sullivan J, Shanley T, Blazar B, Larson R, FitzGerald G, Reis S, Pearson T, Buchanan T, McPherson D, Brasier A, Toto R, Disis M, Drezner M, Bernard G, Clore J, Evanoff B, Imperato-McGinley J, Sherwin R, Pulley J. Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci. 2012 Apr; 5(2):121-9.
View in: PubMed

Butler MO, Imataki O, Yamashita Y, Tanaka M, Ansén S, Berezovskaya A, Metzler G, Milstein MI, Mooney MM, Murray AP, Mano H, Nadler LM, Hirano N. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One. 2012; 7(1):e30229.
View in: PubMed

Imataki O, Ansén S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, Kuzushima K, Nadler LM, Hirano N. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells. J Immunol. 2012 Feb 15; 188(4):1609-19.
View in: PubMed

Tanaka M, Butler MO, Ansén S, Imataki O, Berezovskaya A, Nadler LM, Hirano N. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res. 2011 Aug 15; 17(16):5392-401.
View in: PubMed

Maia S, Pelletier M, Ding J, Hsu YM, Sallan SE, Rao SP, Nadler LM, Cardoso AA. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One. 2011; 6(6):e20787.
View in: PubMed

Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27; 3(80):80ra34.
View in: PubMed

Davies JK, Barbon CM, Voskertchian AR, Nadler LM, Guinan EC. Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. J Vis Exp. 2011 Mar 14; (49).
View in: PubMed

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011 Apr; 52(4):587-96.
View in: PubMed

Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. 2011 Apr; 39(4):457-472.e3.
View in: PubMed

Butler MO, Ansén S, Tanaka M, Imataki O, Berezovskaya A, Mooney MM, Metzler G, Milstein MI, Nadler LM, Hirano N. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol. 2010 Nov; 22(11):863-73.
View in: PubMed

Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 2010 May 15; 70(10):3915-24.
View in: PubMed

Davies JK, Nadler LM, Guinan EC. Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med. 2009 Oct 07; 1(1):1ra3.
View in: PubMed

Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM, Schultze JL, von Bergwelt-Baildon MS. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008 Oct 15; 14(20):6574-9.
View in: PubMed

Ansén S, Butler MO, Berezovskaya A, Murray AP, Stevenson K, Nadler LM, Hirano N. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res. 2008 Oct 01; 14(19):6125-36.
View in: PubMed

Davies JK, Yuk D, Nadler LM, Guinan EC. Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation. 2008 Sep 27; 86(6):854-64.
View in: PubMed

Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008 Sep 01; 14(17):5626-34.
View in: PubMed

Haining WN, Angelosanto J, Brosnahan K, Ross K, Hahn C, Russell K, Drury L, Norton S, Nadler L, Stegmaier K. High-throughput gene expression profiling of memory differentiation in primary human T cells. BMC Immunol. 2008 Aug 01; 9:44.
View in: PubMed

Haining WN, Ebert BL, Subrmanian A, Wherry EJ, Eichbaum Q, Evans JW, Mak R, Rivoli S, Pretz J, Angelosanto J, Smutko JS, Walker BD, Kaech SM, Ahmed R, Nadler LM, Golub TR. Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells. J Immunol. 2008 Aug 01; 181(3):1859-68.
View in: PubMed

Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood. 2008 Sep 15; 112(6):2232-41.
View in: PubMed

Cardoso BA, Martins LR, Santos CI, Nadler LM, Boussiotis VA, Cardoso AA, Barata JT. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia. 2009 Jan; 23(1):206-8.
View in: PubMed

Nadler LM, Roberts WC. Lee Marshall Nadler, MD: a conversation with the editor. Proc (Bayl Univ Med Cent). 2007 Oct; 20(4):381-9.
View in: PubMed

Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1057-65.
View in: PubMed

Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007 Jun 20; 25(18):2554-9.
View in: PubMed

Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67.
View in: PubMed

Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Kojima S, Nadler LM. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood. 2006 Oct 15; 108(8):2662-8.
View in: PubMed

Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Nadler LM. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res. 2006 May 15; 12(10):2967-75.
View in: PubMed

Veiga JP, Costa LF, Sallan SE, Nadler LM, Cardoso AA. Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol. 2006 May; 34(5):610-21.
View in: PubMed

Zander T, Yunes JA, Cardoso AA, Nadler LM. Rapid, reliable and inexpensive quality assessment of biotinylated cRNA. Braz J Med Biol Res. 2006 May; 39(5):589-93.
View in: PubMed

von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, Debey S, Draube A, Maecker B, Menezes I, Nadler LM, Schultze JL. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006 Apr 01; 107(7):2786-9.
View in: PubMed

Maia S, Haining WN, Ansén S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005 Nov 01; 65(21):10050-8.
View in: PubMed

Hirano N, Butler MO, Xia Z, Ansén S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2006 Feb 15; 107(4):1528-36.
View in: PubMed

Costa LF, Balcells M, Edelman ER, Nadler LM, Cardoso AA. Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood. 2006 Jan 01; 107(1):285-92.
View in: PubMed

Maecker B, von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, Schultze JL. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005 Sep; 141(3):558-62.
View in: PubMed

Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
View in: PubMed

Weihrauch MR, Ansén S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, Nadler LM. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5993-6001.
View in: PubMed

Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in: PubMed

Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer. 2005 Jun 10; 115(2):333-6.
View in: PubMed

Haining WN, Neuberg DS, Keczkemethy HL, Evans JW, Rivoli S, Gelman R, Rosenblatt HM, Shearer WT, Guenaga J, Douek DC, Silverman LB, Sallan SE, Guinan EC, Nadler LM. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005 Sep 01; 106(5):1749-54.
View in: PubMed

Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005 Apr 01; 23(10):2208-14.
View in: PubMed

Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94.
View in: PubMed

Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol. 2005 Jan; 128(2):221-3.
View in: PubMed

Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA, Cardoso AA. Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica. 2004 Dec; 89(12):1459-67.
View in: PubMed

Haining WN, Evans JW, Seth NP, Callaway GD, Wucherpfennig KW, Nadler LM, Guinan EC. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol. 2004 Nov; 127(3):322-5.
View in: PubMed

Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15; 105(2):489-95.
View in: PubMed

Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med. 2004 Sep 06; 200(5):659-69.
View in: PubMed

Haining WN, Anderson DG, Little SR, von Bergwelt-Baildon MS, Cardoso AA, Alves P, Kosmatopoulos K, Nadler LM, Langer R, Kohane DS, von Berwelt-Baildon MS. pH-triggered microparticles for peptide vaccination. J Immunol. 2004 Aug 15; 173(4):2578-85.
View in: PubMed

von Bergwelt-Baildon M, Schultze JL, Maecker B, Menezes I, Nadler LM. Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43. Cancer Res. 2004 Jun 01; 64(11):4055-6; author reply 4056-7.
View in: PubMed

Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma. 2004 Feb; 45(2):315-20.
View in: PubMed

Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 01; 10(3):828-39.
View in: PubMed

Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, Sallan SE, Look AT, Nadler LM, Cardoso AA. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 2004 Mar 01; 103(5):1891-900.
View in: PubMed

Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O'Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003 Dec 15; 102(13):4567-75.
View in: PubMed

Tzachanis D, Appleman LJ, Van Puijenbroek AA, Berezovskaya A, Nadler LM, Boussiotis VA. Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification. J Immunol. 2003 Aug 15; 171(4):1691-6.
View in: PubMed

Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 Nov 01; 102(9):3287-94.
View in: PubMed

Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
View in: PubMed

Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3.
View in: PubMed

Nadler LM, Schultze JL. From genomics to cancer vaccines: patient-tailored or universal vaccines? Curr Opin Mol Ther. 2002 Dec; 4(6):572-6.
View in: PubMed

Grader-Beck T, van Puijenbroek AA, Nadler LM, Boussiotis VA. cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood. 2003 Feb 01; 101(3):998-1006.
View in: PubMed

Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 01; 168(11):5900-6.
View in: PubMed

von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002 May 01; 99(9):3319-25.
View in: PubMed

Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol. 2002 Mar 15; 168(6):2729-36.
View in: PubMed

Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood. 2002 Feb 15; 99(4):1465-73.
View in: PubMed

Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001 Dec; 2(12):1174-82.
View in: PubMed

Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001 Dec 01; 61(23):8366-70.
View in: PubMed

Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001 Nov; 7(11):3343-8.
View in: PubMed

Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol. 2001 Nov; 31(11):3261-70.
View in: PubMed

Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL, Nadler LM. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol. 2001 Oct; 19(4):791-8.
View in: PubMed

Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood. 2001 Sep 01; 98(5):1524-31.
View in: PubMed

Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, Sallan SE, Rolink AG, Mantovani A, Nadler LM, Cardoso AA. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 2001 Aug 01; 98(3):533-40.
View in: PubMed

Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Br J Haematol. 2001 May; 113(2):455-60.
View in: PubMed

Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2001; 7(8):446-53.
View in: PubMed

Robinson SN, Freedman AS, Neuberg DS, Nadler LM, Mauch PM. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment. Exp Hematol. 2000 Dec; 28(12):1325-33.
View in: PubMed

Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol. 2000 Sep; 8(3):210-5.
View in: PubMed

Stripecke R, Cardoso AA, Pepper KA, Skelton DC, Yu XJ, Mascarenhas L, Weinberg KI, Nadler LM, Kohn DB. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood. 2000 Aug 15; 96(4):1317-26.
View in: PubMed

Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J. 2000 May-Jun; 6(3):146-50.
View in: PubMed

Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, Nadler LM. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med. 2000 Mar; 6(3):290-7.
View in: PubMed

Cardoso AA, Veiga JP, Ghia P, Afonso HM, Haining WN, Sallan SE, Nadler LM. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood. 1999 Nov 15; 94(10):3531-40.
View in: PubMed

Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33.
View in: PubMed

Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
View in: PubMed

Nadler LM. Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself. Semin Hematol. 1999 Oct; 36(4 Suppl 5):9-11.
View in: PubMed

Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999 Sep; 5(9):2392-8.
View in: PubMed

Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999 Jun 03; 340(22):1704-14.
View in: PubMed

Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun; 10(6):673-9.
View in: PubMed

Boussiotis VA, Freedman AS, Nadler LM. Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol. 1999 Apr; 36(2):209-16.
View in: PubMed

Schultze JL, Nadler LM. T cell mediated immunotherapy for B cell lymphoma. J Mol Med (Berl). 1999 Mar; 77(3):322-31.
View in: PubMed

Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999 Feb 15; 93(4):1287-98.
View in: PubMed

Schultze JL, Michalak S, Lowne J, Wong A, Gilleece MH, Gribben JG, Nadler LM. Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J Exp Med. 1999 Jan 04; 189(1):1-12.
View in: PubMed

Ghia P, Schaniel C, Rolink AG, Nadler LM, Cardoso AA. Human macrophage-derived chemokine (MDC) is strongly expressed following activation of both normal and malignant precursor and mature B cells. Curr Top Microbiol Immunol. 1999; 246:103-10.
View in: PubMed

Schultze JL, Gribben JG, Nadler LM. Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Curr Opin Oncol. 1998 Nov; 10(6):542-7.
View in: PubMed

Multani PS, O'Day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1998 Nov; 4(11):2599-604.
View in: PubMed

Boussiotis VA, Freeman GJ, Gribben JG, Hayes DF, Nadler LM. No evidence for MUC 1-induced apoptosis. Nat Med. 1998 Oct; 4(10):1093.
View in: PubMed

Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, Patel AT, Robertson MJ, Nadler LM, Freeman GJ. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998 Sep 15; 161(6):2780-90.
View in: PubMed

Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, Clark EA, Nadler LM. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol. 1998 Sep 15; 161(6):2708-15.
View in: PubMed

Dorfman DM, Shahsafaei A, Nadler LM, Freeman GJ. The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas. Am J Pathol. 1998 Jul; 153(1):255-62.
View in: PubMed

Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol. 1998 Jul; 102(2):509-15.
View in: PubMed

Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS, Nadler LM, Gribben JG, Gilliland DG. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998 Jun 15; 91(12):4496-503.
View in: PubMed

Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L, Kuhlman C, Murray C, Freeman A, Mauch P, Anderson KC, Nadler LM, Ritz J. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.
View in: PubMed

Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998 Jan 01; 91(1):244-51.
View in: PubMed

Freedman AS, Gribben JG, Nadler LM. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Jan; 28(3-4):219-30.
View in: PubMed

Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
View in: PubMed

Freedman A, Neuberg D, Mauch P, Gribben J, Soiffer R, Anderson K, Robertson M, Fisher DC, Schlossman R, Kroon M, Rhuda C, Kuhlman C, Ritz J, Nadler L. Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001.
View in: PubMed

Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood. 1997 Dec 01; 90(11):4297-306.
View in: PubMed

Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997 Dec 01; 100(11):2757-65.
View in: PubMed

Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997 Nov 15; 90(10):4212-21.
View in: PubMed

Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science. 1997 Oct 03; 278(5335):124-8.
View in: PubMed

Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol. 1997 Oct 01; 159(7):3156-67.
View in: PubMed

Ghia P, Nadler LM. Recent advances in lymphoma biology. Curr Opin Oncol. 1997 Sep; 9(5):403-12.
View in: PubMed

Legare RD, Gribben JG, Maragh M, Hermanowski-Vosatka A, Roach S, Tantravahi R, Nadler LM, Gilliland DG. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol. 1997 Sep; 56(1):45-51.
View in: PubMed

Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997 Jul 15; 90(2):549-61.
View in: PubMed

Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood. 1997 May 15; 89(10):3806-16.
View in: PubMed

Gribben JG, Cardoso AA, Schultze JL, Nadler LM. Biologic response modifiers in acute lymphoblastic leukemia. Leukemia. 1997 May; 11 Suppl 4:S31-3.
View in: PubMed

Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47.
View in: PubMed

Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr; 3(1):11-7.
View in: PubMed

Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, Nadler LM. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med. 1996 Dec; 2(12):1367-70.
View in: PubMed

Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister TA, Armitage JO. Lymphoma classification--the gap between biology and clinical management is closing. Blood. 1996 Dec 01; 88(11):4085-9.
View in: PubMed

Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11780-5.
View in: PubMed

Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev. 1996 Oct; 153:5-26.
View in: PubMed

Keating M, Cheson B, Gribben JG, Robertson B, Nadler L. Innovative strategies for the treatment of CLL. Leuk Lymphoma. 1996 Oct; 22 Suppl 2:53-64.
View in: PubMed

Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6.
View in: PubMed

Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35.
View in: PubMed

Webb IJ, Coral FS, Andersen JW, Elias AD, Finberg RW, Nadler LM, Ritz J, Anderson KC. Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion. 1996 Sep; 36(9):782-8.
View in: PubMed

Boussiotis VA, Pardo NA, Collins H, Houghton A, Ritz J, Nadler LM, Soiffer RJ. R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996 Sep; 26(9):2149-54.
View in: PubMed

Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med. 1996 Aug 01; 184(2):365-76.
View in: PubMed

Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996 Jul 01; 88(1):41-8.
View in: PubMed

Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996 Jun 01; 87(11):4887-93.
View in: PubMed

Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev. 1996 Jun; 10(2):111-27.
View in: PubMed

Zhao J, Freeman GJ, Gray GS, Nadler LM, Glimcher LH. A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. J Exp Med. 1996 Mar 01; 183(3):777-89.
View in: PubMed

Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 01; 156(3):1126-31.
View in: PubMed

Borriello F, Oliveros J, Freeman GJ, Nadler LM, Sharpe AH. Differential expression of alternate mB7-2 transcripts. J Immunol. 1995 Dec 15; 155(12):5490-7.
View in: PubMed

Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8200-4.
View in: PubMed

Ueda Y, Levine BL, Huang ML, Freeman GJ, Nadler LM, June CH, Ward SG. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Int Immunol. 1995 Jun; 7(6):957-66.
View in: PubMed

Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995 May; 2(5):523-32.
View in: PubMed

Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 01; 85(9):2507-15.
View in: PubMed

Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The critical role of CD28 signalling in the prevention of human T-cell anergy. Res Immunol. 1995 Mar-Apr; 146(3):140-9.
View in: PubMed

Seiden MV, Schlossman R, Andersen J, Freeman A, Robertson M, Soiffer R, Freedman A, Mauch P, Ritz J, Nadler L, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995 Mar; 17(1-2):87-93.
View in: PubMed

Spector NL, Hardy L, Ryan C, Miller WH, Humes JL, Nadler LM, Luedke E. 28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells. J Biol Chem. 1995 Jan 20; 270(3):1003-6.
View in: PubMed

Gribben J, Nadler L. Detection of minimal residual disease. Cancer Treat Res. 1995; 76:249-70.
View in: PubMed

Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan; 13(1):239-50.
View in: PubMed

Borriello F, Freeman GJ, Edelhoff S, Disteche CM, Nadler LM, Sharpe AH. Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. J Immunol. 1994 Dec 01; 153(11):5038-48.
View in: PubMed

Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15; 84(10):3261-82.
View in: PubMed

Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D'Andrea AD, Ritz J, Nadler LM. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 1994 Nov 11; 266(5187):1039-42.
View in: PubMed

Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994 Nov 01; 180(5):1665-73.
View in: PubMed

Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994 Oct; 6(5):797-807.
View in: PubMed

Engel P, Gribben JG, Freeman GJ, Zhou LJ, Nozawa Y, Abe M, Nadler LM, Wakasa H, Tedder TF. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood. 1994 Sep 01; 84(5):1402-7.
View in: PubMed

Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol. 1994 Sep 01; 153(5):1990-7.
View in: PubMed

Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A. 1994 Jul 19; 91(15):7007-11.
View in: PubMed

June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994 Jul; 15(7):321-31.
View in: PubMed

Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood. 1994 Jun 15; 83(12):3800-7.
View in: PubMed

Freedman AS, Saporito L, Rhynhart K, Morimoto C, Nadler LM. Adhesion of follicular lymphoma cells to lymphoid germinal centers--a potential mechanism of tumor cell homing following autologous transplantation. Leuk Lymphoma. 1994 Mar; 13(1-2):47-52.
View in: PubMed

Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood. 1994 Feb 01; 83(3):793-8.
View in: PubMed

Spector NL, Mehlen P, Ryan C, Hardy L, Samson W, Levine H, Nadler LM, Fabre N, Arrigo AP. Regulation of the 28 kDa heat shock protein by retinoic acid during differentiation of human leukemic HL-60 cells. FEBS Lett. 1994 Jan 10; 337(2):184-8.
View in: PubMed

Rohatiner AZ, Freedman A, Nadler L, Lim J, Lister TA. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol. 1994; 5 Suppl 2:143-6.
View in: PubMed

Grossbard ML, Nadler LM. Immunotoxin therapy of lymphoid neoplasms. Semin Hematol. 1994 Jan; 31(1):88-97.
View in: PubMed

Gribben JG, Nadler LM. Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. Important Adv Oncol. 1994; 117-29.
View in: PubMed

Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A. 1993 Dec 01; 90(23):11059-63.
View in: PubMed

Gimmi CD, Gribben JG, Freeman GJ, Nadler LM. [Failing B7 costimulation engenders a peripheral clonal T-cell anergy in a human antigen-specific model]. Schweiz Med Wochenschr. 1993 Nov 27; 123(47):2255-6.
View in: PubMed

Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993 Nov 05; 262(5135):909-11.
View in: PubMed

Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med. 1993 Nov 01; 178(5):1753-63.
View in: PubMed

Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, Lombard DB, Freeman GJ, Nadler LM, Gray GS, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol. 1993 Oct 01; 151(7):3489-99.
View in: PubMed

Grossbard ML, Nadler LM. Monoclonal antibody therapy for indolent lymphomas. Semin Oncol. 1993 Oct; 20(5 Suppl 5):118-35.
View in: PubMed

Freedman AS, Nadler LM. Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol. 1993 Oct; 11(10):1841-3.
View in: PubMed

Soiffer RJ, Gonin R, Murray C, Robertson MJ, Cochran K, Chartier S, Cameron C, Daley J, Levine H, Nadler LM, et al. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood. 1993 Oct 01; 82(7):2216-23.
View in: PubMed

Gribben JG, Nadler LM. Monitoring minimal residual disease. Semin Oncol. 1993 Oct; 20(5 Suppl 5):143-55.
View in: PubMed

Spector NL, Ryan C, Samson W, Levine H, Nadler LM, Arrigo AP. Heat shock protein is a unique marker of growth arrest during macrophage differentiation of HL-60 cells. J Cell Physiol. 1993 Sep; 156(3):619-25.
View in: PubMed

Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A. 1993 Jul 15; 90(14):6586-90.
View in: PubMed

Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5687-90.
View in: PubMed

Freedman AS, Nadler LM. Developments in purging in autotransplantation. Hematol Oncol Clin North Am. 1993 Jun; 7(3):687-715.
View in: PubMed

Gribben JG, Nadler LM. The immunological treatment of human marrow in vitro in transplantation biology. Cancer Treat Res. 1993; 64:189-211.
View in: PubMed

Grossbard ML, Nadler LM. Immunotoxin therapy of lymphoma. Cancer Treat Res. 1993; 68:111-31.
View in: PubMed

Gribben JG, Nadler LM. Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphoma. Important Adv Oncol. 1993; 139-56.
View in: PubMed

Galvin F, Freeman GJ, Razi-Wolf Z, Benacerraf B, Nadler L, Reiser H. Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. Eur J Immunol. 1993 Jan; 23(1):283-6.
View in: PubMed

Gribben JG, Nadler LM. Bone marrow purging for autologous bone marrow transplantation. Leuk Lymphoma. 1993; 11 Suppl 2:141-8.
View in: PubMed

Galvin F, Freeman GJ, Razi-Wolf Z, Hall W, Benacerraf B, Nadler L, Reiser H. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol. 1992 Dec 15; 149(12):3802-8.
View in: PubMed

Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature. 1992 Nov 19; 360(6401):266-8.
View in: PubMed

Freedman AS, Munro JM, Rhynhart K, Schow P, Daley J, Lee N, Svahn J, Eliseo L, Nadler LM. Follicular dendritic cells inhibit human B-lymphocyte proliferation. Blood. 1992 Sep 01; 80(5):1284-8.
View in: PubMed

Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood. 1992 Aug 15; 80(4):863-78.
View in: PubMed

Gribben JG, Saporito L, Barber M, Blake KW, Edwards RM, Griffin JD, Freedman AS, Nadler LM. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood. 1992 Aug 15; 80(4):1083-9.
View in: PubMed

Grossbard ML, Lambert JM, Goldmacher VS, Blättler WA, Nadler LM. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin. Cancer Res. 1992 Aug 01; 52(15):4200-7.
View in: PubMed

LaSalle JM, Tolentino PJ, Freeman GJ, Nadler LM, Hafler DA. Early signaling defects in human T cells anergized by T cell presentation of autoantigen. J Exp Med. 1992 Jul 01; 176(1):177-86.
View in: PubMed

Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 01; 79(9):2229-36.
View in: PubMed

Razi-Wolf Z, Freeman GJ, Galvin F, Benacerraf B, Nadler L, Reiser H. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci U S A. 1992 May 01; 89(9):4210-4.
View in: PubMed

Vandenberghe P, Freeman GJ, Nadler LM, Fletcher MC, Kamoun M, Turka LA, Ledbetter JA, Thompson CB, June CH. Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med. 1992 Apr 01; 175(4):951-60.
View in: PubMed

Spector NL, Samson W, Ryan C, Gribben J, Urba W, Welch WJ, Nadler LM. Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (Hsp28). J Immunol. 1992 Mar 15; 148(6):1668-73.
View in: PubMed

Freeman GJ, Disteche CM, Gribben JG, Adler DA, Freedman AS, Dougery J, Nadler LM. The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. Blood. 1992 Jan 15; 79(2):489-94.
View in: PubMed

Schriever F, Nadler LM. The central role of follicular dendritic cells in lymphoid tissues. Adv Immunol. 1992; 51:243-84.
View in: PubMed

Reiser H, Freeman GJ, Razi-Wolf Z, Gimmi CD, Benacerraf B, Nadler LM. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci U S A. 1992 Jan 01; 89(1):271-5.
View in: PubMed

Freedman AS, Munro JM, Morimoto C, McIntyre BW, Rhynhart K, Lee N, Nadler LM. Follicular non-Hodgkin's lymphoma cell adhesion to normal germinal centers and neoplastic follicles involves very late antigen-4 and vascular cell adhesion molecule-1. Blood. 1992 Jan 01; 79(1):206-12.
View in: PubMed

Grossbard ML, Nadler LM. Immunotoxin therapy of malignancy. Important Adv Oncol. 1992; 111-35.
View in: PubMed

Gribben JG, Freedman As, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS, Nadler LM. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 1991 Dec 15; 78(12):3275-80.
View in: PubMed

Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C, Tarbell NJ, Mauch P, Nadler LM, Ritz J. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991 Dec; 52(6):1014-9.
View in: PubMed

Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res. 1991 Dec 01; 51(23 Pt 1):6236-42.
View in: PubMed

Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991 Oct 15; 137(2):429-37.
View in: PubMed

Freedman AS, Nadler LM. Immunologic markers in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 1991 Oct; 5(5):871-89.
View in: PubMed

Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med. 1991 Sep 01; 174(3):625-31.
View in: PubMed

Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A. 1991 Aug 01; 88(15):6575-9.
View in: PubMed

Rabinowe SN, Nemunaitis J, Armitage J, Nadler LM. The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol. 1991 Apr; 28(2 Suppl 2):6-16.
View in: PubMed

Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6.
View in: PubMed

Freedman AS, Nadler LM. Cellular interactions within the germinal centre. Res Immunol. 1991 Mar-Apr; 142(3):232-6.
View in: PubMed

Schriever F, Freeman G, Nadler LM. Follicular dendritic cells contain a unique gene repertoire demonstrated by single-cell polymerase chain reaction. Blood. 1991 Feb 15; 77(4):787-91.
View in: PubMed

Freedman AS, Pedrazzini A, Nadler LM. B-cell monoclonal antibodies and their use in clinical oncology. Cancer Invest. 1991; 9(1):69-84.
View in: PubMed

Kaplan WD, Jochelson MS, Herman TS, Nadler LM, Stomper PC, Takvorian T, Andersen JW, Canellos GP. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol. 1990 Dec; 8(12):1966-70.
View in: PubMed

Jochelson M, Tarbell NJ, Freedman AS, Rabinowe SN, Takvorian T, Soiffer R, Anderson K, Ritz J, Nadler LM. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1990 Nov; 6(5):329-31.
View in: PubMed

Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706.
View in: PubMed

Freedman AS, Munro JM, Rice GE, Bevilacqua MP, Morimoto C, McIntyre BW, Rhynhart K, Pober JS, Nadler LM. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science. 1990 Aug 31; 249(4972):1030-3.
View in: PubMed

Dadmarz R, Rabinowe SN, Cannistra SA, Andersen JW, Freedman AS, Nadler LM. Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia. Blood. 1990 Jul 01; 76(1):142-9.
View in: PubMed

Anderson KC, Soiffer R, DeLage R, Takvorian T, Freedman AS, Rabinowe SL, Nadler LM, Dear K, Heflin L, Mauch P, et al. T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood. 1990 Jul 01; 76(1):235-44.
View in: PubMed

Vallé A, Garrone P, Yssel H, Bonnefoy JY, Freedman AS, Freeman G, Nadler LM, Banchereau J. mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells. Immunology. 1990 Apr; 69(4):531-5.
View in: PubMed

Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC, Freedman AS, Nadler LM, Ritz J. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 1990 Jan 01; 75(1):296-304.
View in: PubMed

Freedman AS, Nadler LM. The relationship of chronic lymphocytic leukemia to normal activated B cells. Leuk Lymphoma. 1990; 1(5-6):293-300.
View in: PubMed

Spector NL, Freedman AS, Freeman G, Segil J, Whitman JF, Welch WJ, Nadler LM. Activation primes human B lymphocytes to respond to heat shock. J Exp Med. 1989 Nov 01; 170(5):1763-8.
View in: PubMed

Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989 Oct 15; 143(8):2714-22.
View in: PubMed

Bashir R, Freedman A, Harris N, Bain K, Nadler L, Hochberg F. Immunophenotypic profile of CNS lymphoma: a review of eighteen cases. J Neurooncol. 1989 Sep; 7(3):249-54.
View in: PubMed

Pedrazzini A, Freedman AS, Nadler LM. Autologous bone-marrow transplantation in non-Hodgkin's lymphomas. Biochim Biophys Acta. 1989 Jul 28; 989(1):11-24.
View in: PubMed

Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J, Nadler LM. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med. 1989 Jun 01; 169(6):2043-58.
View in: PubMed

Bosserman LD, Murray C, Takvorian T, Anderson KC, Freedman AS, Fitzsimmons J, Coral F, Nadler LM, Schlossman SF, Ritz J. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989 May; 4(3):239-45.
View in: PubMed

Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May; 83(5):1512-8.
View in: PubMed

Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Levine H, Nadler LM. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol. 1989 May; 19(5):849-55.
View in: PubMed

Anderson KC, Barut BA, Ritz J, Freedman AS, Nadler LM. Autologous bone marrow transplantation therapy for multiple myeloma. Eur J Haematol Suppl. 1989; 51:157-63.
View in: PubMed

Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Nadler LM. Studies of in vitro activated CD5+ B cells. Blood. 1989 Jan; 73(1):202-8.
View in: PubMed

Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Nadler LM. Pre-exposure of human B cells to recombinant IL-1 enhances subsequent proliferation. J Immunol. 1988 Nov 15; 141(10):3398-404.
View in: PubMed

Canellos GP, Nadler L, Takvorian T. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):58-65.
View in: PubMed

Freedman AS, Takvorian T, Nadler LM, Anderson KC, Sallan SE, Ritz J. Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Cancer Treat Res. 1988; 38:265-83.
View in: PubMed

Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM. B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol. 1987 Nov 15; 139(10):3260-7.
View in: PubMed

Freedman AS, Nadler LM. B cell development in chronic lymphocytic leukemia. Semin Hematol. 1987 Oct; 24(4):230-9.
View in: PubMed

Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC, Levy DN, Nadler LM. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood. 1987 Aug; 70(2):418-27.
View in: PubMed

Freedman AS, Nadler LM. Cell surface markers in hematologic malignancies. Semin Oncol. 1987 Jun; 14(2):193-212.
View in: PubMed

Boyd AW, Tedder TF, Griffin JD, Freedman AS, Fisher DC, Daley J, Nadler LM. Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. Cell Immunol. 1987 May; 106(2):355-65.
View in: PubMed

Umiel T, Nadler LM, Cohen IJ, Levine H, Stark B, Mammon Z, Dzaldetti M, Rechavi G, Simoni F, Katzir N, et al. Undifferentiated leukemia of infancy with t(11:17) chromosomal rearrangement. Coexpressing myeloid and B cell restricted antigens. Cancer. 1987 Mar 15; 59(6):1143-9.
View in: PubMed

Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Canellos GP, Schlossman SF, Nadler LM. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
View in: PubMed

Anderson KC, Nadler LM, Takvorian T, Freedman AS, Canellos GP, Schlossman SF, Ritz J. Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
View in: PubMed

Letvin NL, Zalutsky MR, Lambert JM, Chalifoux LV, Nadler LM, Schlossman SF, Atkins HL. Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys. Int J Rad Appl Instrum B. 1987; 14(2):99-105.
View in: PubMed

Freedman AS, Boyd AW, Berrebi A, Horowitz JC, Levy DN, Rosen KJ, Daley J, Slaughenhoupt B, Levine H, Nadler LM. Expression of B cell activation antigens on normal and malignant B cells. Leukemia. 1987 Jan; 1(1):9-15.
View in: PubMed

Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol. 1986 Aug; 16(8):881-7.
View in: PubMed

Dörken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S, Nadler LM. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol. 1986 Jun 15; 136(12):4470-9.
View in: PubMed

Anderson KC, Roach JA, Daley JF, Schlossman SF, Nadler LM. Dual fluorochrome analysis of human B lymphocytes: phenotypic examination of resting, anti-immunoglobulin stimulated, and in vivo activated B cells. J Immunol. 1986 May 15; 136(10):3612-8.
View in: PubMed

Boyd AW, Freedman AS, Horowitz JC, Anderson KC, Fisher DC, Rosen KJ, Schlossman SF, Nadler LM. Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of the role of autocrine effects on B-cell proliferation and of T-cell help in B-cell differentiation. Cell Immunol. 1986 Apr 15; 99(1):228-40.
View in: PubMed

Bregni M, De Fabritiis P, Raso V, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Cancer Res. 1986 Mar; 46(3):1208-13.
View in: PubMed

Natali P, Bigotti A, Cavalieri R, Nicotra MR, Tecce R, Manfredi D, Chen YX, Nadler LM, Ferrone S. Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. Hum Immunol. 1986 Feb; 15(2):220-33.
View in: PubMed

Anderson KC, Nadler LM. Bone marrow transplantation in the therapy of non-Hodgkin's lymphomas. Important Adv Oncol. 1986; 287-310.
View in: PubMed

Umiel T, Nadler LM, Levine H, Cohen IJ, Stark B, Zaizov R. Acute leukemia with mixed lymphoid and myeloid phenotype. Br J Haematol. 1986 Jan; 62(1):196-7.
View in: PubMed

De Fabritiis P, Bregni M, Lipton J, Reynolds C, Nadler L, Ritz J, Bast RC. Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res. 1986; 10(1):35-42.
View in: PubMed

Hokland P, Ritz J, Schlossman SF, Nadler LM. Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol. 1985 Sep; 135(3):1746-51.
View in: PubMed

Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985 Aug; 135(2):973-9.
View in: PubMed

De Fabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood. 1985 May; 65(5):1064-70.
View in: PubMed

Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol. 1985 May; 134(5):3007-12.
View in: PubMed

Boyd AW, Fisher DC, Fox DA, Schlossman SF, Nadler LM. Structural and functional characterization of IL 2 receptors on activated human B cells. J Immunol. 1985 Apr; 134(4):2387-92.
View in: PubMed

Freedman AS, Boyd AW, Anderson KC, Fisher DC, Schlossman SF, Nadler LM. B5, a new B cell-restricted activation antigen. J Immunol. 1985 Apr; 134(4):2228-35.
View in: PubMed

Boyd AW, Anderson KC, Freedman AS, Fisher DC, Slaughenhoupt B, Schlossman SF, Nadler LM. Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol. 1985 Mar; 134(3):1516-23.
View in: PubMed

Freedman AS, Boyd AW, Anderson KC, Fisher DC, Pinkus GS, Schlossman SF, Nadler LM. Immunologic heterogeneity of diffuse large cell lymphoma. Blood. 1985 Mar; 65(3):630-7.
View in: PubMed

Anderson KC, Boyd AW, Fisher DC, Leslie D, Schlossman SF, Nadler LM. Hairy cell leukemia: a tumor of pre-plasma cells. Blood. 1985 Mar; 65(3):620-9.
View in: PubMed

Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast R, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res. 1985 Feb; 45(2):758-67.
View in: PubMed

Anderson KC, Boyd AW, Fisher DC, Slaughenhoupt B, Groopman JE, O'Hara CJ, Daley JF, Schlossman SF, Nadler LM. Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets. J Immunol. 1985 Feb; 134(2):820-7.
View in: PubMed

Bast RC, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503.
View in: PubMed

Marti GE, Nadler LM, Chused TM, Tosato G, Blaese RM, Kindt TJ. Cellular distribution of a human I-A-like (DS/DC) antigen on normal and neoplastic lymphoid cells. Hum Immunol. 1985 Jan; 12(1):23-35.
View in: PubMed

Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol. 1984 Nov; 117(2):262-72.
View in: PubMed

Antman KH, Nadler L, Mark EJ, Montella DL, Kirkpatrick P, Halpern J. Primary Kaposi's sarcoma of the lung in an immunocompetent 32-year-old heterosexual white man. Cancer. 1984 Oct 15; 54(8):1696-8.
View in: PubMed

Hokland P, Nadler LM, Griffin JD, Schlossman SF, Ritz J. Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
View in: PubMed

Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 1984 Aug 25; 2(8400):427-31.
View in: PubMed

Hurley CK, Giles RC, Nunez G, DeMars R, Nadler L, Winchester R, Stastny P, Capra JD. Molecular localization of human class II MT2 and MT3 determinants. J Exp Med. 1984 Aug 01; 160(2):472-93.
View in: PubMed

Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, Jensen J, Coral F, Mayer RJ, Sallan SE, et al. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984 Aug; 74(2):332-40.
View in: PubMed

Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984 Jun; 63(6):1424-33.
View in: PubMed

Anderson KC, Bates MP, Slaughenhoupt B, Schlossman SF, Nadler LM. A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol. 1984 Jun; 132(6):3172-9.
View in: PubMed

Linch DC, Nadler LM, Luther EA, Lipton JM. Discordant expression of human Ia-like antigens on hematopoietic progenitor cells. J Immunol. 1984 May; 132(5):2324-9.
View in: PubMed

Letvin NL, Aldrich WR, Thorley-Lawson DA, Schlossman SF, Nadler LM. Surface antigen changes during B-lymphocyte activation in primates. Cell Immunol. 1984 Mar; 84(1):163-70.
View in: PubMed

Iida K, Nadler L, Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med. 1983 Oct 01; 158(4):1021-33.
View in: PubMed

Fram RJ, Skarin AT, Rosenthal DS, Pinkus G, Nadler LM. Clinical, pathologic and immunologic features of patients with non-Hodgkin's lymphoma in a leukemic phase. A retrospective analysis of 34 patients. Cancer. 1983 Oct 01; 52(7):1220-8.
View in: PubMed

Lipton JM, Nadler LM, Canellos GP, Kudisch M, Reiss CS, Nathan DG. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest. 1983 Aug; 72(2):694-706.
View in: PubMed

Anderson KC, Griffin JD, Bates MP, Slaughenhoupt BL, Schlossman SF, Nadler LM. Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. J Immunol Methods. 1983 Jul 29; 61(3):283-92.
View in: PubMed

Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF, Nadler LM. Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol. 1983 Jul; 131(1):232-7.
View in: PubMed

Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983 Jul; 131(1):244-50.
View in: PubMed

Anderson KC, Park EK, Bates MP, Leonard RC, Hardy R, Schlossman SF, Nadler LM. Antigens on human plasma cells identified by monoclonal antibodies. J Immunol. 1983 Mar; 130(3):1132-8.
View in: PubMed

Kufe DW, Nadler L, Sargent L, Shapiro H, Hand P, Austin F, Colcher D, Schlom J. Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res. 1983 Feb; 43(2):851-7.
View in: PubMed

Hokland P, Rosenthal P, Griffin JD, Nadler LM, Daley J, Hokland M, Schlossman SF, Ritz J. Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 01; 157(1):114-29.
View in: PubMed

Oettgen HC, Bayard PJ, Van Ewijk W, Nadler LM, Terhorst CP. Further biochemical studies of the human B-cell differentiation antigens B1 and B2. Hybridoma. 1983; 2(1):17-28.
View in: PubMed

Griffin JD, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D, Schlossman SF. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
View in: PubMed

Hurley CK, Shaw S, Nadler L, Schlossman S, Capra JD. Alpha and beta chains of SB and DR antigens are structurally distinct. J Exp Med. 1982 Nov 01; 156(5):1557-62.
View in: PubMed

Thorley-Lawson DA, Schooley RT, Bhan AK, Nadler LM. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell. 1982 Sep; 30(2):415-25.
View in: PubMed

Shaw S, DeMars R, Schlossman SF, Smith PL, Lampson LA, Nadler LM. Serologic identification of the human secondary B cell antigens. Correlations between function, genetics, and structure. J Exp Med. 1982 Sep 01; 156(3):731-43.
View in: PubMed

Nadler LM, Ritz J, Bates MP, Park EK, Anderson KC, Sallan SE, Schlossman SF. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest. 1982 Aug; 70(2):433-42.
View in: PubMed

Posner MR, Said J, Pinkus GS, Nadler LM, Hardy R, Flatow F, Skarin AT. T-cell lymphoblastic lymphoma with subsequent acute nonlymphocytic leukemia: a case report. Cancer. 1982 Jul 01; 50(1):118-24.
View in: PubMed

Morimoto C, Reinherz EL, Nadler LM, Distaso JA, Steinberg AD, Schlossman SF. Comparison in T- and B-cell markers in patients with Sjögren's syndrome and systemic lupus erythematosus. Clin Immunol Immunopathol. 1982 Feb; 22(2):270-8.
View in: PubMed

McAdam KP, Li J, Knowles J, Foss NT, Dinarello CA, Rosenwasser LJ, Selinger MJ, Kaplan MM, Goodman R, Herbert PN, Bausserman LL, Nadler LM. The biology of SAA: identification of the inducer, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies. Ann N Y Acad Sci. 1982; 389:126-36.
View in: PubMed

Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov; 68(5):1331-7.
View in: PubMed

Hercend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF, Ritz J. Expression of a 26,000-dalton glycoprotein on activated human T cells. Cell Immunol. 1981 Oct; 64(1):192-9.
View in: PubMed

Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
View in: PubMed

Posner MR, Reinherz EL, Breard J, Nadler LM, Rosenthal DS, Schlossman SF. Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin's disease. Cancer. 1981 Sep 01; 48(5):1170-6.
View in: PubMed

Bhan AK, Nadler LM, Stashenko P, McCluskey RT, Schlossman SF. Stages of B cell differentiation in human lymphoid tissue. J Exp Med. 1981 Sep 01; 154(3):737-49.
View in: PubMed

Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM, Schlossman SF. Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood. 1981 Sep; 58(3):648-52.
View in: PubMed

Pesando JM, Nadler LM, Lazarus H, Tomaselli KJ, Stashenko P, Ritz J, Levine H, Yunis EJ, Schlossman SF. Human cell lines express multiple populations of Ia-like molecules. Hum Immunol. 1981 Aug; 3(1):67-76.
View in: PubMed

Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Valensi F, Dausset J, Flandrin G, Lemerle J, Schlossman SF. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 1981 Jun; 57(6):1105-10.
View in: PubMed

Stashenko P, Nadler LM, Hardy R, Schlossman SF. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A. 1981 Jun; 78(6):3848-52.
View in: PubMed

Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF. Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol. 1981 May; 126(5):1941-7.
View in: PubMed

Nadler LM, Stashenko P, Hardy R, Tomaselli KJ, Yunis EJ, Schlossman SF, Pesando JM. Monoclonal antibody identifies a new Ia-like (p29,34) polymorphic system linked to the HLA-D/DR region. Nature. 1981 Apr 16; 290(5807):591-3.
View in: PubMed

Todd RF, Nadler LM, Schlossman SF. Antigens on human monocytes identified by monoclonal antibodies. J Immunol. 1981 Apr; 126(4):1435-42.
View in: PubMed

Boumsell L, Bernard A, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Dubertret L, Valensi F, Degos L, Lemerle J, Flandrin G, Dausset J, Schlossman SF. Surface antigens on malignant Sézary and T-CLL cells correspond to those of mature T cells. Blood. 1981 Mar; 57(3):526-30.
View in: PubMed

Nadler LM, Stashenko P, Hardy R, Pesando JM, Yunis EJ, Schlossman SF. Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man. Hum Immunol. 1981 Feb; 2(1):77-90.
View in: PubMed

Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981 Jan; 67(1):134-40.
View in: PubMed

Todd RF, Griffin JD, Ritz J, Nadler LM, Abrams T, Schlossman SF. Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
View in: PubMed

Nadler LM, Ritz J, Griffin JD, Todd RF, Reinherz EL, Schlossman SF. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
View in: PubMed

Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980 Oct; 125(4):1678-85.
View in: PubMed

Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep; 40(9):3147-54.
View in: PubMed

Nadler LM, Stashenko P, Hardy R, Schlossman SF. A monoclonal antibody defining a lymphoma-associated antigen in man. J Immunol. 1980 Aug; 125(2):570-7.
View in: PubMed

Nadler LM, Reinherz EL, Weinstein HJ, D'Orsi CJ, Schlossman SF. Heterogeneity of T-cell lymphoblastic malignancies. Blood. 1980 May; 55(5):806-10.
View in: PubMed

Nadler LM, Reinherz EL, Schlossman SF. The T lymphoblastic malignancies. Cancer Chemother Pharmacol. 1980; 4(1):11-5.
View in: PubMed

Pinkus GS, Hargreaves HK, McLeod JA, Nadler LM, Rosenthal DS, Said JW. alpha-Naphthyl acetate esterase activity--a cytochemical marker for T lymphocytees. Correlation with immunologic studies of normal tissues, lymphocytic leukemias, non-Hodgkin's lymphomas, Hodgkin's disease, and other lymphoproliferative disorders. Am J Pathol. 1979 Oct; 97(1):17-41.
View in: PubMed

Reinherz EL, Nadler LM, Sallan SE, Schlossman SF. Subset derivation of T-cell acute lymphoblastic leukemia in man. J Clin Invest. 1979 Aug; 64(2):392-7.
View in: PubMed

Reinherz EL, Nadler LM, Rosenthal DS, Moloney WC, Schlossman SF. T-cell-subset characterization of human T-CLL. Blood. 1979 Jun; 53(6):1066-75.
View in: PubMed

Hodes RJ, Nadler LM, Hathcock KS. Regulatory mechanisms in cell-mediated immune responses. III. Antigen-specific and nonspecific suppressor activities generated during MLC. J Immunol. 1977 Sep; 119(3):961-7.
View in: PubMed

Nadler LM, Hodes RJ. Regulatory mechanisms in cell-mediated immune responses. II. Comparison of culture-induced and alloantigen-induced suppressor cells in MLR and CML. J Immunol. 1977 May; 118(5):1886-95.
View in: PubMed

Top